Literature DB >> 34789503

Obesity Partially Mediates the Diabetogenic Effect of Lowering LDL Cholesterol.

Peitao Wu1, Jee-Young Moon2, Iyas Daghlas3,4, Giulianini Franco5, Bianca C Porneala6, Fariba Ahmadizar7, Tom G Richardson8,9, Jonas L Isaksen10, Georgy Hindy11, Jie Yao12, Colleen M Sitlani13, Laura M Raffield14, Lisa R Yanek15, Mary F Feitosa16, Rafael R C Cuadrat17,18, Qibin Qi2, M Arfan Ikram7, Christina Ellervik19,20, Ulrika Ericson11, Mark O Goodarzi21, Jennifer A Brody13, Leslie Lange22, Josep M Mercader4,23,24, Dhananjay Vaidya15, Ping An16, Matthias B Schulze17,18,25, Lluis Masana26,27, Mohsen Ghanbari7, Morten S Olesen28,29, Jianwen Cai30, Xiuqing Guo12, James S Floyd13,31, Susanne Jäger17,18, Michael A Province16, Rita R Kalyani15, Bruce M Psaty13,31,32, Marju Orho-Melander11, Paul M Ridker5,24, Jørgen K Kanters10, Andre Uitterlinden7,33, George Davey Smith8, Dipender Gill9,34,35,36, Robert C Kaplan2,37, Maryam Kavousi7, Sridharan Raghavan38,39, Daniel I Chasman3,4, Jerome I Rotter12, James B Meigs4,6,24, Jose C Florez4,23,24, Josée Dupuis1, Ching-Ti Liu1, Jordi Merino4,23,24,26.   

Abstract

OBJECTIVE: LDL cholesterol (LDLc)-lowering drugs modestly increase body weight and type 2 diabetes risk, but the extent to which the diabetogenic effect of lowering LDLc is mediated through increased BMI is unknown. RESEARCH DESIGN AND METHODS: We conducted summary-level univariable and multivariable Mendelian randomization (MR) analyses in 921,908 participants to investigate the effect of lowering LDLc on type 2 diabetes risk and the proportion of this effect mediated through BMI. We used data from 92,532 participants from 14 observational studies to replicate findings in individual-level MR analyses.
RESULTS: A 1-SD decrease in genetically predicted LDLc was associated with increased type 2 diabetes odds (odds ratio [OR] 1.12 [95% CI 1.01, 1.24]) and BMI (β = 0.07 SD units [95% CI 0.02, 0.12]) in univariable MR analyses. The multivariable MR analysis showed evidence of an indirect effect of lowering LDLc on type 2 diabetes through BMI (OR 1.04 [95% CI 1.01, 1.08]) with a proportion mediated of 38% of the total effect (P = 0.03). Total and indirect effect estimates were similar across a number of sensitivity analyses. Individual-level MR analyses confirmed the indirect effect of lowering LDLc on type 2 diabetes through BMI with an estimated proportion mediated of 8% (P = 0.04).
CONCLUSIONS: These findings suggest that the diabetogenic effect attributed to lowering LDLc is partially mediated through increased BMI. Our results could help advance understanding of adipose tissue and lipids in type 2 diabetes pathophysiology and inform strategies to reduce diabetes risk among individuals taking LDLc-lowering medications.
© 2021 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34789503      PMCID: PMC8753762          DOI: 10.2337/dc21-1284

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   17.152


  39 in total

1.  Impact of simvastatin on adipose tissue: pleiotropic effects in vivo.

Authors:  Tayeba Khan; Mark P Hamilton; Dorothy I Mundy; Streamson C Chua; Philipp E Scherer
Journal:  Endocrinology       Date:  2009-10-09       Impact factor: 4.736

2.  Different time trends of caloric and fat intake between statin users and nonusers among US adults: gluttony in the time of statins?

Authors:  Takehiro Sugiyama; Yusuke Tsugawa; Chi-Hong Tseng; Yasuki Kobayashi; Martin F Shapiro
Journal:  JAMA Intern Med       Date:  2014-07       Impact factor: 21.873

3.  Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.

Authors:  David Preiss; Sreenivasa Rao Kondapally Seshasai; Paul Welsh; Sabina A Murphy; Jennifer E Ho; David D Waters; David A DeMicco; Philip Barter; Christopher P Cannon; Marc S Sabatine; Eugene Braunwald; John J P Kastelein; James A de Lemos; Michael A Blazing; Terje R Pedersen; Matti J Tikkanen; Naveed Sattar; Kausik K Ray
Journal:  JAMA       Date:  2011-06-22       Impact factor: 56.272

4.  HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.

Authors:  Daniel I Swerdlow; David Preiss; Karoline B Kuchenbaecker; Michael V Holmes; Jorgen E L Engmann; Tina Shah; Reecha Sofat; Stefan Stender; Paul C D Johnson; Robert A Scott; Maarten Leusink; Niek Verweij; Stephen J Sharp; Yiran Guo; Claudia Giambartolomei; Christina Chung; Anne Peasey; Antoinette Amuzu; KaWah Li; Jutta Palmen; Philip Howard; Jackie A Cooper; Fotios Drenos; Yun R Li; Gordon Lowe; John Gallacher; Marlene C W Stewart; Ioanna Tzoulaki; Sarah G Buxbaum; Daphne L van der A; Nita G Forouhi; N Charlotte Onland-Moret; Yvonne T van der Schouw; Renate B Schnabel; Jaroslav A Hubacek; Ruzena Kubinova; Migle Baceviciene; Abdonas Tamosiunas; Andrzej Pajak; Roman Topor-Madry; Urszula Stepaniak; Sofia Malyutina; Damiano Baldassarre; Bengt Sennblad; Elena Tremoli; Ulf de Faire; Fabrizio Veglia; Ian Ford; J Wouter Jukema; Rudi G J Westendorp; Gert Jan de Borst; Pim A de Jong; Ale Algra; Wilko Spiering; Anke H Maitland-van der Zee; Olaf H Klungel; Anthonius de Boer; Pieter A Doevendans; Charles B Eaton; Jennifer G Robinson; David Duggan; John Kjekshus; John R Downs; Antonio M Gotto; Anthony C Keech; Roberto Marchioli; Gianni Tognoni; Peter S Sever; Neil R Poulter; David D Waters; Terje R Pedersen; Pierre Amarenco; Haruo Nakamura; John J V McMurray; James D Lewsey; Daniel I Chasman; Paul M Ridker; Aldo P Maggioni; Luigi Tavazzi; Kausik K Ray; Sreenivasa Rao Kondapally Seshasai; JoAnn E Manson; Jackie F Price; Peter H Whincup; Richard W Morris; Debbie A Lawlor; George Davey Smith; Yoav Ben-Shlomo; Pamela J Schreiner; Myriam Fornage; David S Siscovick; Mary Cushman; Meena Kumari; Nick J Wareham; W M Monique Verschuren; Susan Redline; Sanjay R Patel; John C Whittaker; Anders Hamsten; Joseph A Delaney; Caroline Dale; Tom R Gaunt; Andrew Wong; Diana Kuh; Rebecca Hardy; Sekar Kathiresan; Berta A Castillo; Pim van der Harst; Eric J Brunner; Anne Tybjaerg-Hansen; Michael G Marmot; Ronald M Krauss; Michael Tsai; Josef Coresh; Ronald C Hoogeveen; Bruce M Psaty; Leslie A Lange; Hakon Hakonarson; Frank Dudbridge; Steve E Humphries; Philippa J Talmud; Mika Kivimäki; Nicholas J Timpson; Claudia Langenberg; Folkert W Asselbergs; Mikhail Voevoda; Martin Bobak; Hynek Pikhart; James G Wilson; Alex P Reiner; Brendan J Keating; Aroon D Hingorani; Naveed Sattar
Journal:  Lancet       Date:  2014-09-24       Impact factor: 79.321

5.  Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.

Authors:  Robert A Scott; Nicholas J Wareham; Luca A Lotta; Stephen J Sharp; Stephen Burgess; John R B Perry; Isobel D Stewart; Sara M Willems; Jian'an Luan; Eva Ardanaz; Larraitz Arriola; Beverley Balkau; Heiner Boeing; Panos Deloukas; Nita G Forouhi; Paul W Franks; Sara Grioni; Rudolf Kaaks; Timothy J Key; Carmen Navarro; Peter M Nilsson; Kim Overvad; Domenico Palli; Salvatore Panico; Jose-Ramón Quirós; Elio Riboli; Olov Rolandsson; Carlotta Sacerdote; Elena C Salamanca; Nadia Slimani; Annemieke Mw Spijkerman; Anne Tjonneland; Rosario Tumino; Daphne L van der A; Yvonne T van der Schouw; Mark I McCarthy; Inês Barroso; Stephen O'Rahilly; David B Savage; Naveed Sattar; Claudia Langenberg
Journal:  JAMA       Date:  2016-10-04       Impact factor: 56.272

6.  Network Mendelian randomization: using genetic variants as instrumental variables to investigate mediation in causal pathways.

Authors:  Stephen Burgess; Rhian M Daniel; Adam S Butterworth; Simon G Thompson
Journal:  Int J Epidemiol       Date:  2014-08-22       Impact factor: 7.196

7.  The MR-Base platform supports systematic causal inference across the human phenome.

Authors:  Gibran Hemani; Jie Zheng; Benjamin Elsworth; Tom R Gaunt; Philip C Haycock; Kaitlin H Wade; Valeriia Haberland; Denis Baird; Charles Laurin; Stephen Burgess; Jack Bowden; Ryan Langdon; Vanessa Y Tan; James Yarmolinsky; Hashem A Shihab; Nicholas J Timpson; David M Evans; Caroline Relton; Richard M Martin; George Davey Smith
Journal:  Elife       Date:  2018-05-30       Impact factor: 8.140

8.  Understanding the consequences of education inequality on cardiovascular disease: mendelian randomisation study.

Authors:  Alice R Carter; Dipender Gill; Neil M Davies; Amy E Taylor; Taavi Tillmann; Julien Vaucher; Robyn E Wootton; Marcus R Munafò; Gibran Hemani; Rainer Malik; Sudha Seshadri; Daniel Woo; Stephen Burgess; George Davey Smith; Michael V Holmes; Ioanna Tzoulaki; Laura D Howe; Abbas Dehghan
Journal:  BMJ       Date:  2019-05-22

9.  Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.

Authors:  Brian A Ference; Jennifer G Robinson; Robert D Brook; Alberico L Catapano; M John Chapman; David R Neff; Szilard Voros; Robert P Giugliano; George Davey Smith; Sergio Fazio; Marc S Sabatine
Journal:  N Engl J Med       Date:  2016-12-01       Impact factor: 91.245

10.  An Expanded Genome-Wide Association Study of Type 2 Diabetes in Europeans.

Authors:  Robert A Scott; Laura J Scott; Reedik Mägi; Letizia Marullo; Kyle J Gaulton; Marika Kaakinen; Natalia Pervjakova; Tune H Pers; Andrew D Johnson; John D Eicher; Anne U Jackson; Teresa Ferreira; Yeji Lee; Clement Ma; Valgerdur Steinthorsdottir; Gudmar Thorleifsson; Lu Qi; Natalie R Van Zuydam; Anubha Mahajan; Han Chen; Peter Almgren; Ben F Voight; Harald Grallert; Martina Müller-Nurasyid; Janina S Ried; Nigel W Rayner; Neil Robertson; Lennart C Karssen; Elisabeth M van Leeuwen; Sara M Willems; Christian Fuchsberger; Phoenix Kwan; Tanya M Teslovich; Pritam Chanda; Man Li; Yingchang Lu; Christian Dina; Dorothee Thuillier; Loic Yengo; Longda Jiang; Thomas Sparso; Hans A Kestler; Himanshu Chheda; Lewin Eisele; Stefan Gustafsson; Mattias Frånberg; Rona J Strawbridge; Rafn Benediktsson; Astradur B Hreidarsson; Augustine Kong; Gunnar Sigurðsson; Nicola D Kerrison; Jian'an Luan; Liming Liang; Thomas Meitinger; Michael Roden; Barbara Thorand; Tõnu Esko; Evelin Mihailov; Caroline Fox; Ching-Ti Liu; Denis Rybin; Bo Isomaa; Valeriya Lyssenko; Tiinamaija Tuomi; David J Couper; James S Pankow; Niels Grarup; Christian T Have; Marit E Jørgensen; Torben Jørgensen; Allan Linneberg; Marilyn C Cornelis; Rob M van Dam; David J Hunter; Peter Kraft; Qi Sun; Sarah Edkins; Katharine R Owen; John R B Perry; Andrew R Wood; Eleftheria Zeggini; Juan Tajes-Fernandes; Goncalo R Abecasis; Lori L Bonnycastle; Peter S Chines; Heather M Stringham; Heikki A Koistinen; Leena Kinnunen; Bengt Sennblad; Thomas W Mühleisen; Markus M Nöthen; Sonali Pechlivanis; Damiano Baldassarre; Karl Gertow; Steve E Humphries; Elena Tremoli; Norman Klopp; Julia Meyer; Gerald Steinbach; Roman Wennauer; Johan G Eriksson; Satu Mӓnnistö; Leena Peltonen; Emmi Tikkanen; Guillaume Charpentier; Elodie Eury; Stéphane Lobbens; Bruna Gigante; Karin Leander; Olga McLeod; Erwin P Bottinger; Omri Gottesman; Douglas Ruderfer; Matthias Blüher; Peter Kovacs; Anke Tonjes; Nisa M Maruthur; Chiara Scapoli; Raimund Erbel; Karl-Heinz Jöckel; Susanne Moebus; Ulf de Faire; Anders Hamsten; Michael Stumvoll; Panagiotis Deloukas; Peter J Donnelly; Timothy M Frayling; Andrew T Hattersley; Samuli Ripatti; Veikko Salomaa; Nancy L Pedersen; Bernhard O Boehm; Richard N Bergman; Francis S Collins; Karen L Mohlke; Jaakko Tuomilehto; Torben Hansen; Oluf Pedersen; Inês Barroso; Lars Lannfelt; Erik Ingelsson; Lars Lind; Cecilia M Lindgren; Stephane Cauchi; Philippe Froguel; Ruth J F Loos; Beverley Balkau; Heiner Boeing; Paul W Franks; Aurelio Barricarte Gurrea; Domenico Palli; Yvonne T van der Schouw; David Altshuler; Leif C Groop; Claudia Langenberg; Nicholas J Wareham; Eric Sijbrands; Cornelia M van Duijn; Jose C Florez; James B Meigs; Eric Boerwinkle; Christian Gieger; Konstantin Strauch; Andres Metspalu; Andrew D Morris; Colin N A Palmer; Frank B Hu; Unnur Thorsteinsdottir; Kari Stefansson; Josée Dupuis; Andrew P Morris; Michael Boehnke; Mark I McCarthy; Inga Prokopenko
Journal:  Diabetes       Date:  2017-05-31       Impact factor: 9.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.